| Name | Title | Contact Details |
|---|
One of the fastest growing companies in America, Shields Health Solutions partners with hospital leaders on every aspect of specialty pharmacy creation and growth. The company provides the fastest, lowest risk model for Hospital leaders to create and grow a hospital-owned specialty pharmacy business, whether starting from scratch or adding specialty capabilities to a hospital`s existing pharmacy programs.
Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology.
Onsite Partners, Inc. is a holding company of behavioral services organizations: Onsite Workshops, Milestones, and Onsite at The Oaks. The Onsite family of brands provides services to thousands of clients annually from the United States and Europe, through in-person and virtual settings. Through these companies, Onsite curates transformational emotional health experiences that combine some of the best therapeutic and clinical minds in the country with its signature healing hospitality. Recently Onsite launched a series of virtual emotional health courses and will be expanding this platform in 2021. Onsite offers experiential group programs, counseling intensives, digital courses, and innovative residential trauma treatment that bolster empathy, self-awareness, compassion, and resilience. Onsite`s mission is to change lives through enhanced emotional health. Onsite`s work has been featured on 20/20, Good Morning America, New York Times, Wall Street Journal, Marie Claire, People, Dr. Phil Show, and The Doctors.
At Baby+Company we want to change the world one birth at a time… We`re driven by a passion to expand women`s choices -to make what can feel like a choice between two extremes, hospital delivery and home birth, into a spectrum of options. Not because we don`t support these other models of care, but because for many women, neither feels like the right fit. So we`re building birth centers that celebrate the individuality of our families— through a model of care that brings together the centuries-old tradition of midwifery with the very best research, resources and data available today.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.